We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Improved Medical Imaging and Drug Development May Result from Reference Isotope

By Biotechdaily staff writers
Posted on 28 Jan 2008
An increasingly popular radioactive isotope now has its own reference stand-in. More...
The isotope may ultimately improve medical imaging, speed up clinical trials of many drugs, and facilitate efforts to develop more individualized medical treatment.

The number of medical images obtained through the technique known as positron emission tomography (PET) imaging is increasing at a rate of 20% per year, and this has correspondingly increased the use of fluorine-18, the radioactive isotope of choice in the vast majority of PET procedures. Injected into the bloodstream while bound to "carrier” molecules, fluorine-18 lights up the body during PET scans to perform such tasks as revealing tumors, tracking heart activity, and determining which regions of the brain are active during specific tasks.

However, fluorine-18 has a very short life --a batch of the compound decays to half its initial quantity in fewer than two hours, and less than one ten-thousandth of the original amount is left after a single day. Because the isotope decays so rapidly, it is not possible for a single central lab to make precise measurements on fluorine-18 solutions and then distribute them to remote centers to calibrate PET machines. This lack of a "standard reference” for fluorine-18 means that PET-related measurements from center to center, from patient to patient, and even in the same patient over time, are difficult or impossible to compare with one another.

Researchers from the U.S. National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) collaborating with a nuclear medicine company called RadQual (Concord, NH, USA), have looked to germanium-68 as a calibration surrogate for fluorine-18. This germanium isotope is much longer lived--its half-life is 270.95 days--but its radiation decay characteristics are otherwise similar to fluorine-18. Small differences between measurements of germanium-68 and fluorine-18 can be accounted for through the use of mathematic conversion factors. Germanium-68 never would be used in actual PET procedures; it would only be used to calibrate the machines properly, enabling more accurate measurements of the fluorine-18 isotopes. Although germanium-68 has been used for performing corrections on PET scanners, the industry has lacked a traceable standard reference material for instrument calibration.

NIST researchers have calibrated solutions of germanium-68 that could become the basis of a new standard reference material for this isotope. The next phase of this project involves working with RadQual to calibrate a new "mock” syringe standard that would use germanium-68 embedded in an epoxy to simulate fluorine-18 in a syringe. This would help researchers more accurately determine the amount of fluorine-18 to be injected into patients during the PET procedure so as to minimize radiation dose while still generating the best image. NIST is also working independently on a germanium-68-based PET "phantom” that can be used to calibrate PET scanners in a way that is traceable back to NIST.

The first commercial products from this collaboration may be reaching PET centers later in 2008. By giving clinicians more effective results on how specific patients are responding to cancer treatments and providing more accurate indications earlier in clinical trials as to how individual patients are metabolizing specific drugs, better standards for PET imaging may hasten the arrival of customized medicine.


Related Links:
National Institute of Standards and Technology
RadQual

New
Gold Member
Aspiration System
VACUSAFE
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Plasma pTau217 testing can predict future amyloid accumulation and cognitive decline in cognitively healthy older adults (photo courtesy of Shutterstock)

Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms

Alzheimer's disease often advances silently for years, making timely risk stratification difficult in routine practice. Current approaches to detect pathology can involve lumbar puncture or positron emission... Read more

Industry

view channel
Image: The GenoPredict assay from Predicta Biosciences is available to Tempus Life Sciences partners to support exploratory research and clinical development programs (photo courtesy of Shutterstock)

Partnership Expands Ultrasensitive WGS Assay for for Hematologic Malignancies and MRD Monitoring

Tempus AI and Predicta Biosciences announced the commercial expansion of a co-branded whole‑genome sequencing assay GenoPredicta, which is intended for comprehensive genomic characterization of hematologic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.